

## Correction


**Correction: Long-term prognostic implications and therapeutic target role of hexokinase II in patients with nasopharyngeal carcinoma****Meng-Xia Zhang<sup>1,2,\*</sup>, Yi-Jun Hua<sup>1,2,\*</sup>, Hai-Yun Wang<sup>1,3</sup>, Ling Zhou<sup>1</sup>, Hai-Qiang Mai<sup>1,2</sup>, Xiang Guo<sup>1,2</sup>, Chong Zhao<sup>1,4</sup>, Wen-Lin Huang<sup>1</sup>, Ming-Huang Hong<sup>1,2</sup> and Ming-Yuan Chen<sup>1,2</sup>**<sup>1</sup>State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, P. R. China<sup>2</sup>Department of Nasopharyngeal Carcinoma, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong 510060, P. R. China<sup>3</sup>Department of Pathology, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong 510060, P. R. China<sup>4</sup>Department of Radiotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong 510060, P. R. China

\*These authors have contributed equally to this work



**Published:****Copyright:** © 2022 Zhang et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**This article has been corrected:** In Figure 4, the ‘5-8F’ group contains an accidental overlap from the image in the ‘CNE2 group’ in the *3-BrOP Hypoxia* row, and the ‘CNE2’ group contains an accidental overlap from the image in the ‘5-8F group’ in the *Control* row. The corrected Figure 4, obtained using the original data, is shown below. In the *Results* section as well as in the legend for Figure 6, the text stating, “Effect of the combination of 3-BrOP and cisplatin on NPC cells under normoxic and hypoxic conditions” is written incorrectly. The effect of the combination of 3-BrOP and cisplatin on CNE2 cells was in fact under normoxic conditions, in order to detect the effect under normal conditions. The correct figure legend for Figure 6 is provided below. Additionally, in the preparation of Figure 6B, only partial WB bands of B (3-BrOP), C (cisplatin) and B+C (3-BrOP + cisplatin) groups related to this article were provided. The original and entire WB figure is now shown below for reference (Supplementary Figure 1). The authors declare that these corrections do not change the results or conclusions of this paper.


Original article: Oncotarget. 2016; 7:21287–21297. <https://doi.org/10.18632/oncotarget.7116>



**Figure 4: 3-BrOP suppresses the invasion ability of NPC cells.** 5-8F and CNE-2 cells were cultured with 3-BrOP under hypoxic and normoxic conditions. Cells without any treatments were adopted as controls. The cell invasion ability was detected by transwell assay.



**Figure 6: Combination of 3-BrOP and cisplatin on NPC cells under normoxic condition.** (A) Apoptosis of CNE2 cells treated with 3-BrOP (B), cisplatin (C) or the combination group (B+C) was detected by flow cytometry after treatment for 24 h and 48 h; (B) Apoptosis-related proteins were detected by western blot.



**Supplementary Figure 1:** The expression of mTOR, phosphorylated mTOR (p-mTOR), AKT, phosphorylated AKT (p-AKT), caspase 3, caspase 9 and PARP-p89 in CNE2 cells stimulated by 3-BrOP (B), rapamycin (R), cisplatin (C) along and combinations were detected by western blotting.